{"id":4021,"date":"2020-08-26T09:18:22","date_gmt":"2020-08-26T09:18:22","guid":{"rendered":"https:\/\/clinlabint.3wstaging.nl\/quikread-go-crp-test-cleared-in-the-us\/"},"modified":"2021-01-08T11:27:23","modified_gmt":"2021-01-08T11:27:23","slug":"quikread-go-crp-test-cleared-in-the-us","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/quikread-go-crp-test-cleared-in-the-us\/","title":{"rendered":"QuikRead go CRP test cleared in the US"},"content":{"rendered":"
Orion Diagnostica\u2019s QuikRead go CRP test received clearance from the US FDA to market the device for clinical laboratories. The QuikRead go test system measures C-reactive protein (CRP) in whole blood, plasma and serum in 2 minutes. The system consists of a small device and a ready-to-use reagent kit with all the materials for performing the test. This easy-to-use system is in wide use worldwide. The tests available for the system outside US includes CRP, CRP+Hb, Strep A and iFOBT. Measurement of CRP aids in the evaluation of injury to body tissues, and infection and inflammatory disorders. The advantages of measuring CRP lie in it being a sensitive, early, and reliable reflector of the acute-phase response. Quantitative measurement of CRP concentration has been reported to be a sensitive indicator of the efficacy of antimicrobial therapy and the course of bacterial infections. The rise in CRP level is non-specific. <\/p>\n
\nSupplier:<\/strong> Orion Diagnostica Oy
\nWebsite:<\/strong> <\/a><\/p>\n